Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience

• Published in: Radiation oncology journal Vol. 34; no. 2; pp. 106 - 112
• Main Authors: Choi, Euncheol, Kim, Jin Hee, Kim, Ok Bae, Kim, Mi Young, Oh, Young Ki, Baek, Sung Gyu
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society for Radiation Oncology 01.06.2016; 대한방사선종양학회
• Subjects: Original; 방사선과학; Stage; Rectal neoplasms; Chemoradiotherapy; Rectum; Interval
• ISSN: 2234-1900; 2234-3156; 2234-3164
• DOI: 10.3857/roj.2015.01585

To identify possible predictors of pathologic complete response (pCR) of rectal cancer after preoperative concurrent chemoradiotherapy (CCRT). We conducted a retrospective review of 53 patients with rectal cancer who underwent preoperative CCRT followed by radical surgery at a single center between January 2007 and December 2012. The median radiotherapy dose to the pelvis was 54.0 Gy (range, 45.0 to 63.0 Gy). Five-fluorouracil-based chemotherapy was administered via continuous infusion with leucovorin. The pCR rate was 20.8%. The downstaging rate was 66%. In univariate analyses, poor and undifferentiated tumors (p = 0.020) and an interval of ≥7 weeks from finishing CCRT to surgery (p = 0.040) were significantly associated with pCR, while female gender (p = 0.070), initial carcinoembryonic antigen concentration of <5.0 ng/dL (p = 0.100), and clinical stage T2 (p = 0.100) were marginally significant factors. In multivariate analysis, an interval of ≥7 weeks from finishing CCRT to surgery (odds ratio, 0.139; 95% confidence interval, 0.022 to 0.877; p = 0.036) was significantly associated with pCR, while stage T2 (odds ratio, 5.363; 95% confidence interval, 0.963 to 29.877; p = 0.055) was a marginally significant risk factor. We suggest that the interval from finishing CCRT to surgery is a predictor of pCR after preoperative CCRT in patients with rectal cancer. Stage T2 cancer may also be an important predictive factor. We hope to perform a robust study by collecting data during treatment to obtain more advanced results.